-
公开(公告)号：US20240335375A1
公开(公告)日：2024-10-10
申请号：US18294739
申请日：2022-08-03
发明人： Jean CUINE , Boris BIZET , Frédéric LALLEMAND , Jean GARREC , Stéphane GIBAUD , Anne SAPIN-MINET
CPC分类号： A61K9/0048 , A61K45/06 , A61K47/36
摘要： An ocular delivery system useful for the treatment of glaucoma in subject in need thereof. Especially, a mucoadhesive solid or semisolid ocular delivery system that includes a matrix of preactivated thiomer of hyaluronic acid and one or more anti-glaucoma drugs. The ocular delivery system may be an ocular insert or an ocular film.
-
公开(公告)号：US20200011572A1
公开(公告)日：2020-01-09
申请号：US16493037
申请日：2018-03-12
发明人： David Mercs , Fabien Capon , Nicolas Portha , Alexis Boileau
IPC分类号： F24S70/20 , C23C14/00 , C23C14/08 , C23C14/34 , C23C14/58 , C23C14/06 , F24S40/50 , F24S70/30
摘要： Thermoregulated multilayer material characterized in that it comprises at least one substrate and one thermoregulated layer, said thermoregulated multilayer material having: for λ radiation of between 0.25 and 2 μm, an absorption coefficient αm≥0.8; and, for incident λ radiation of between 7.5 and 10 μm, a reflection coefficient ρm: ρm≥0.85, when the temperature T of said multilayer material 1 is ≤100° C.; ρm between 0.3 and 0.85, when the temperature T of said multilayer material is between 0 and 400° C.
-
3.发明申请INHIBITING PEPTIDES DERIVED FROM TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF 有权抑制在MYELOID细胞-1（TREM-1）TREM-LIKE转录物1（TLT-1）上表达的触发受体衍生的肽及其用途公开(公告)号：US20150232531A1
公开(公告)日：2015-08-20
申请号：US14426562
申请日：2013-09-09
IPC分类号： C07K14/705
CPC分类号： C07K14/70503
摘要： The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
摘要翻译： 本发明涉及包含至少6个选自氨基酸序列SEQ ID NO：2的连续氨基酸和功能保守变体的肽。 本发明还涉及包含至少6个选自氨基酸序列SEQ ID NO：1或SEQ ID NO：2的连续氨基酸的肽和用于治疗心血管疾病的功能保守变体。
-
4.发明公开公开(公告)号：US20240158889A1
公开(公告)日：2024-05-16
申请号：US18282192
申请日：2022-03-16
发明人： Laszlo TOTH , Satish Vasu KAILAS , Yajun ZHAO , Abhishek PARIYAR , Marc PONÇOT , Marc NOVELLI , Viet Quoc VU
IPC分类号： C22C1/053
CPC分类号： C22C1/053
摘要： The present disclosure is in the field of metal matrix polymer derived ceramic composites, processes of production and uses thereof. In particular, the disclosure concerns metal matrix polymer derived ceramic composites comprising ceramic nanoparticles, processes of production comprising a step of severe plastic deformation, and uses thereof.
-
公开(公告)号：US11963984B2
公开(公告)日：2024-04-23
申请号：US16488253
申请日：2018-02-28
发明人： Danièle Bensoussan , Sébastien Gibot , Loïc Reppel , Caroline Laroye , Amir Boufenzer , Léonore Avercenc , Céline Huselstein
IPC分类号： A61K35/51
CPC分类号： A61K35/51
摘要： The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.
-
公开(公告)号：US20220396885A1
公开(公告)日：2022-12-15
申请号：US17772659
申请日：2020-10-16
申请人： L'Air Liquide Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude , Centre National de la Recherche Scientifique , Université de Lorraine
IPC分类号： C23C24/08
摘要： A process for the deposition of a coating on at least a part of a metallic substrate, a) mixing a liquid and a powder having particles of a metallic material to be deposited and particles of a pickling agent, so as to prepare a suspension, b) application of the suspension prepared in step a) to at least a part of the surfaces of the metallic substrate, so as to obtain a substrate-suspension assembly, c) carrying out a heat treatment of the assembly which includes heating at a first temperature of at least 500° C. and heating at a second temperature greater than the first temperature, and d) recovery of a substrate coated, at least in part, with a coating, the pickling agent being a halogenated compound and the suspension having from 10% to 60% of the pickling agent, with respect to the total weight of the powder.
-
公开(公告)号：US20220143908A1
公开(公告)日：2022-05-12
申请号：US17435216
申请日：2020-02-25
申请人： UNIVERSITÉ DE LORRAINE , CENTRE EUROPEEN DE RECHERCHES ET DE FORMATION AUX ARTS VERRIERS (CERFAV)
发明人： Gérard JEANDEL , Marie-Alice SKAPER , Denis GARCIA , Simon AUFRANC , Guilherme VIANNA-SANTOS , Damien BRISSINGER
IPC分类号： B29C64/153 , C03B19/06 , B23K26/34 , B29C64/268
摘要： The invention proposes a device for three-dimensional printing of a glass object, by applying and solidifying successive layers of a material constituting the glass, in locations corresponding to the section of the object to be produced in the corresponding layer, by means of a laser producing a beam whose wavelength allows the direct fusion in the core of the material.
The device comprises: means for supplying the material to a support on which the successive layers are formed; means for thermal regulation of the successive layers for holding their temperature during the production of the object and for cooling them after the production of the object; a central unit controlling the laser. The printing device comprises means for servo-controlling the power and the speed of the laser in real time.-
公开(公告)号：US20190262363A1
公开(公告)日：2019-08-29
申请号：US16320135
申请日：2017-07-25
发明人： Anne PIZARD , Chaohua DENG , Hervé KEMPF , Arnaud BIANCHI , David MOULIN , Nathalie PRESLE
IPC分类号： A61K31/585 , A61P19/02 , A61K31/713 , A61K31/7105 , C12N15/113 , A61K9/00
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of osteoarthritis. The inventors showed that accumulated metabolic risk factors, hypertension, obesity, dyslipidemia, insulin resistance (known as metabolic syndrome), lead to severe osteoarthritis articular phenotype. They showed in rats that preventive and chronic mineralocorticoid receptor antagonist eplerenone treatment can improve the metabolic syndrome related osteoarthritis. In particular, the present invention relates to an antagonist of mineralocorticoid receptor for use in a method for the treatment of osteoarthritis in a subject in need thereof.
-
9.发明申请Methods and Pharmaceutical Compositions for the Treatment of Cardiovascular Fibrosis 有权用于治疗心血管纤维化的方法和药物组合物公开(公告)号：US20150247855A1
公开(公告)日：2015-09-03
申请号：US14426563
申请日：2013-09-27
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE LORRAINE , HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU)
IPC分类号： G01N33/573
CPC分类号： C12N15/113 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K39/3955 , C07K14/47 , C07K16/18 , C07K2317/76 , C12N15/115 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/16 , G01N33/573 , G01N2500/04 , G01N2800/325
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
摘要翻译： 本发明涉及用于治疗心血管纤维化的方法和药物组合物。 特别地，本发明涉及用于治疗或预防有需要的受试者的心血管纤维化的方法中的嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）活性或表达的抑制剂。
-
公开(公告)号：US20240301497A1
公开(公告)日：2024-09-12
申请号：US17769474
申请日：2020-10-16
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE LORRAINE , CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU)
IPC分类号： C12Q1/6886 , A61B10/02
CPC分类号： C12Q1/6886 , A61B10/02 , A61B2010/0216 , C12Q2600/154 , C12Q2600/158
摘要： The present invention relates to methods and compositions for the diagnostic and for the treatment of nasal intestinal type adenocarcinomas (ITAC). The inventors used a non-invasive brushing technique, which permits to identify transcriptomic and methylation modifications that are consistent with phenotypic profiles and ITACs natural history. Thus, they identified CACNA1C as a new predictive marker of ITAC. In particular, the invention relates to a method of determining whether a subject has or is at risk of having nasal intestinal type adenocarcinoma (ITAC) comprising determining the expression level of CACNA1C in a sample wherein said expression level indicates whether the subject has or is at risk of having a nasal intestinal type adenocarcinoma (ITAC).
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.018 秒)
